Fortress Biotech, Inc. (FBIOP) 株式分析

企業概要

Fortress Biotech, Inc. (FBIOP) is a biopharmaceutical enterprise dedicated to the development and commercialization of specialized biopharmaceutical products within the healthcare sector. Operating specifically in the biotechnology industry, the company focuses on bringing innovative therapies to market, such as Emrosi, an extended-release minocycline hydrochloride capsule designed for rosacea treatment, and Qbrexza, a medicated clotrimazole formulation. The company currently maintains a market capitalization of $73.97M, reflecting its valuation as a small-cap entity with an annual revenue of $63.26M, while the specific count of its employees is not publicly disclosed in the available data. These financial figures position the firm as a mid-to-small scale player within the broader biotechnology landscape, indicating a company that is generating significant top-line revenue but operates with a valuation that suggests a smaller market footprint compared to large-cap peers. The revenue generation of over $63 million provides the necessary cash flow to fund its R&D pipeline, although the relatively modest market cap implies that the stock price does not yet fully reflect the potential long-term value of its product portfolio or future commercialization milestones.

財務健全性

The company reported a trailing twelve-month revenue of $63.26M, yet this top-line figure masks a net income loss of $-1,882,000 and an EBITDA of $-65,560,000, revealing a cost structure where operating expenses significantly outweigh gross profits. The substantial gap between the positive revenue and negative net income indicates that overhead costs, research and development expenditures, and general administrative expenses are consuming the majority of the gross margin. Free cash flow stands at $-47,286,376, which highlights a period of negative liquidity generation typical for biotechnology firms that are heavily investing in clinical trials and product development before achieving profitability. The gross margin is reported at 48.1%, suggesting that the cost of goods sold for its dermatology products is managed reasonably well, yet the operating margin of -29.8% and profit margin of 10.8% demonstrate that high operational costs are eroding bottom-line profitability. On the balance sheet, the company holds $79.38M in cash against $67.22M in debt, resulting in a debt-to-equity ratio of 108.09, which indicates a highly leveraged position rather than a conservative one. Despite the high leverage, the current ratio of 2.49 suggests that the company maintains adequate short-term liquidity to cover its immediate obligations without immediate distress. Furthermore, the return on equity is -108.7% and the return on assets is -26.6%, metrics that reveal that management effectiveness in generating returns on shareholder capital and asset base is currently negative due to the company's unprofitable status.

バリュエーション評価

The trailing P/E ratio is not available due to the company's lack of net income, and the forward P/E is also not available, implying that earnings-based valuation multiples are currently inapplicable for assessing future expected earnings trajectories. The price-to-book ratio stands at 7.65, indicating that the market is valuing the company at a significant premium of 7.65 times its book value, which is common in biotechnology sectors where intangible assets and intellectual property drive value rather than tangible book equity. Alternative valuation metrics such as the price-to-sales ratio of 1.17 and the EV/EBITDA of -6.77 provide additional context, suggesting that investors are pricing the stock based on revenue potential rather than current profitability or earnings power. The stock has traded between a 52-week high of $14.64 and a 52-week low of $4.72, meaning the current price sits somewhere within this volatile range, reflecting the high uncertainty associated with small-cap biotech valuations. With a beta of 1.45, the stock exhibits price volatility that is 45% higher than the broader market, signaling that the asset class is significantly more sensitive to market fluctuations than large-cap blue-chip stocks.

Growth & Income

Fortress Biotech, Inc. achieved a revenue growth rate of 6.3% year-over-year, while earnings growth is not available due to the company's ongoing losses, indicating that top-line expansion is outpacing the ability to generate profit at this stage. As the company does not pay dividends, the dividend yield and payout ratio are not applicable, meaning that the firm reinvests all available cash flow directly into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is standard for biopharmaceutical companies that must fund expensive clinical trials and regulatory approvals to extend their product lifecycles and enter new markets. The overall growth and income profile of the company is characterized by steady revenue expansion and a complete reliance on internal capital generation or external financing to sustain operations, rather than providing current income to investors.